Article ID Journal Published Year Pages File Type
1918778 Maturitas 2006 9 Pages PDF
Abstract

ObjectivesTo study the fracture reducing potential of hormone replacement therapy (HRT) at a population level, the effect of age on the fracture reducing potential of HRT, and to examine whether socio-economic factors confound the effects of HRT on fracture risk.Subjects and methodsCase–control study. All women who sustained any fracture during the year 2000 in Denmark served as cases (n = 64,548). For each case, three age-matched controls were randomly drawn from the background population (n = 193,641). The main exposure was the average daily dose of HRT (expressed as defined daily doses DDD/day). Adjustments were made for co-morbidity, socio-economic factors, and prior fracture.ResultsA fracture risk reduction was seen in women aged ≥50 years using ≥0.3 DDD/day. The risk reduction for any fracture was larger in women aged ≥60 years (0.3–0.99 DDD/day: odds ratio (OR) = 0.77, 95% confidence intervals (CI): 0.73–0.82, ≥1 DDD/day: OR = 0.61, 95% CI: 0.56–0.67) than in women aged 50–59 years (0.3–0.99 DDD/day: OR = 0.92, 95% CI: 0.85–0.99, ≥1 DDD/day: OR = 0.77, 95% CI: 0.70–0.84). Larger risk reductions were seen for Colles’ fractures (age 50–59 years: OR = 0.64 for 0.3–0.99 DDD/day, and OR = 0.57 for ≥1 DDD/day, age ≥60 years: OR = 0.52 for 0.3–0.99 DDD/day, and OR = 0.40 for ≥1 DDD/day). Adjustment only changed the estimates little. No difference between oral and dermal preparations could be found.ConclusionsHormonal replacement therapy possesses a fracture-reducing potential at population level even at dosages lower than usually recommended. The risk reduction was larger with advancing age for any fracture and Colles’ fractures.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Ageing
Authors
, , ,